LOGIN
AAOS 2025: Costal Chondrocyte Pellet ACI vs Microfracture for Articular cartilage defect.
March 2025
AAOS 2025: Costal Chondrocyte Pellet ACI vs Microfracture for Articular cartilage defect.
Study Type:Randomized Trial
OE Level Evidence:N/A
Journal Level of Evidence:N/A
Costal ChondrocyteDerived PelletType Autologous Chondrocyte Implantation for Treatment of Articular Cartilage Defect: a Randomized Phase 3 Clinical Trial Compared to Microfracture
Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
CONFERENCE ACE REPORTS
This ACE Report is a summary of a conference presentation or abstract. The information provided has limited the ability to provide an accurate assessment of the risk of bias or the overall quality. Please interpret the results with caution as trials may be in progress and select results may have been presented.
Synopsis
One hundred four patients with ICRS grade 3 or 4 articular cartilage defects of the knee (2–10 cm² in area, ≤4 cm³ in volume) were randomized to receive CCP-ACI (n=52) or MFx (n=52). The primary outcome of interest was the Magnetic Resonance Observation of Cartilage Repair Tissue (MOCART) score. Secondary outcomes of interest included complete defect repair, tissue integration, signal intensity of...
To view the full content, login to your account,
or start your 30-day FREE Trial today.
FREE TRIAL
LOGIN
Forgot Password?
Explore some of our unlocked ACE Reports below!
Learn about our AI Driven
High Impact Search Feature
Our AI driven High Impact metric calculates the impact an article will have by considering both the publishing journal and the content of the article itself. Built using the latest advances in natural language processing, OE High Impact predicts an article’s future number of citations better than impact factor alone.
Continue
Join the Conversation
Please Login or Join to leave comments.